Pasithea Therapeutics (KTTA) Cash & Equivalents (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Cash & Equivalents for 4 consecutive years, with $9.4 million as the latest value for Q3 2024.
- Quarterly Cash & Equivalents fell 9.11% to $9.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Sep 2024, down 9.11% year-over-year, with the annual reading at $16.3 million for FY2023, 50.64% down from the prior year.
- Cash & Equivalents hit $9.4 million in Q3 2024 for Pasithea Therapeutics, up from $7.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $53.0 million in Q4 2021 to a low of $7.1 million in Q2 2024.
- Historically, Cash & Equivalents has averaged $27.6 million across 4 years, with a median of $26.6 million in 2023.
- Biggest five-year swings in Cash & Equivalents: surged 106.16% in 2022 and later tumbled 75.71% in 2023.
- Year by year, Cash & Equivalents stood at $53.0 million in 2021, then tumbled by 37.53% to $33.1 million in 2022, then tumbled by 50.64% to $16.3 million in 2023, then plummeted by 42.68% to $9.4 million in 2024.
- Business Quant data shows Cash & Equivalents for KTTA at $9.4 million in Q3 2024, $7.1 million in Q2 2024, and $12.0 million in Q1 2024.